|
Gene: PTTG1 |
Gene summary for PTTG1 |
Gene summary. |
Gene information | Species | Human | Gene symbol | PTTG1 | Gene ID | 9232 |
Gene name | PTTG1 regulator of sister chromatid separation, securin | |
Gene Alias | EAP1 | |
Cytomap | 5q33.3 | |
Gene Type | protein-coding | GO ID | GO:0000003 | UniProtAcc | O95997 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
9232 | PTTG1 | GSM4909281 | Human | Breast | IDC | 4.73e-09 | 4.09e-01 | 0.21 |
9232 | PTTG1 | GSM4909282 | Human | Breast | IDC | 1.51e-30 | 6.71e-01 | -0.0288 |
9232 | PTTG1 | GSM4909285 | Human | Breast | IDC | 1.11e-16 | 4.70e-01 | 0.21 |
9232 | PTTG1 | GSM4909287 | Human | Breast | IDC | 3.85e-08 | 4.19e-01 | 0.2057 |
9232 | PTTG1 | GSM4909311 | Human | Breast | IDC | 3.11e-02 | -1.12e-01 | 0.1534 |
9232 | PTTG1 | GSM4909319 | Human | Breast | IDC | 1.35e-06 | 6.14e-02 | 0.1563 |
9232 | PTTG1 | M2 | Human | Breast | IDC | 1.92e-02 | 3.59e-01 | 0.21 |
9232 | PTTG1 | NCCBC5 | Human | Breast | DCIS | 5.07e-04 | 3.19e-01 | 0.2046 |
9232 | PTTG1 | P1 | Human | Breast | IDC | 8.01e-05 | 2.28e-01 | 0.1527 |
9232 | PTTG1 | P2 | Human | Breast | IDC | 8.53e-03 | 2.73e-01 | 0.21 |
9232 | PTTG1 | LZE2T | Human | Esophagus | ESCC | 1.01e-05 | 1.68e+00 | 0.082 |
9232 | PTTG1 | LZE4T | Human | Esophagus | ESCC | 2.71e-08 | 6.88e-01 | 0.0811 |
9232 | PTTG1 | LZE7T | Human | Esophagus | ESCC | 4.27e-02 | 4.34e-01 | 0.0667 |
9232 | PTTG1 | LZE20T | Human | Esophagus | ESCC | 3.28e-03 | 6.01e-01 | 0.0662 |
9232 | PTTG1 | LZE22D1 | Human | Esophagus | HGIN | 6.50e-05 | 1.94e-01 | 0.0595 |
9232 | PTTG1 | LZE6T | Human | Esophagus | ESCC | 9.30e-20 | 1.51e+00 | 0.0845 |
9232 | PTTG1 | P2T-E | Human | Esophagus | ESCC | 3.51e-22 | 1.48e+00 | 0.1177 |
9232 | PTTG1 | P4T-E | Human | Esophagus | ESCC | 2.70e-38 | 1.67e+00 | 0.1323 |
9232 | PTTG1 | P5T-E | Human | Esophagus | ESCC | 2.19e-62 | 2.12e+00 | 0.1327 |
9232 | PTTG1 | P9T-E | Human | Esophagus | ESCC | 2.15e-25 | 1.44e+00 | 0.1131 |
Page: 1 2 3 4 5 6 7 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:001095126 | Thyroid | HT | negative regulation of endopeptidase activity | 40/1272 | 252/18723 | 4.32e-07 | 1.92e-05 | 40 |
GO:001046627 | Thyroid | HT | negative regulation of peptidase activity | 41/1272 | 262/18723 | 4.59e-07 | 2.02e-05 | 41 |
GO:000989629 | Thyroid | HT | positive regulation of catabolic process | 63/1272 | 492/18723 | 8.49e-07 | 3.45e-05 | 63 |
GO:003133129 | Thyroid | HT | positive regulation of cellular catabolic process | 56/1272 | 427/18723 | 1.63e-06 | 6.16e-05 | 56 |
GO:003450420 | Thyroid | HT | protein localization to nucleus | 42/1272 | 290/18723 | 2.68e-06 | 9.37e-05 | 42 |
GO:190179630 | Thyroid | HT | regulation of signal transduction by p53 class mediator | 20/1272 | 93/18723 | 3.39e-06 | 1.13e-04 | 20 |
GO:200124328 | Thyroid | HT | negative regulation of intrinsic apoptotic signaling pathway | 20/1272 | 98/18723 | 7.87e-06 | 2.23e-04 | 20 |
GO:007233229 | Thyroid | HT | intrinsic apoptotic signaling pathway by p53 class mediator | 17/1272 | 76/18723 | 1.04e-05 | 2.81e-04 | 17 |
GO:000691325 | Thyroid | HT | nucleocytoplasmic transport | 39/1272 | 301/18723 | 7.81e-05 | 1.38e-03 | 39 |
GO:005116925 | Thyroid | HT | nuclear transport | 39/1272 | 301/18723 | 7.81e-05 | 1.38e-03 | 39 |
GO:003033026 | Thyroid | HT | DNA damage response, signal transduction by p53 class mediator | 14/1272 | 72/18723 | 3.00e-04 | 4.02e-03 | 14 |
GO:004351610 | Thyroid | HT | regulation of DNA damage response, signal transduction by p53 class mediator | 9/1272 | 34/18723 | 3.33e-04 | 4.28e-03 | 9 |
GO:001703820 | Thyroid | HT | protein import | 27/1272 | 206/18723 | 7.79e-04 | 8.53e-03 | 27 |
GO:001063925 | Thyroid | HT | negative regulation of organelle organization | 39/1272 | 348/18723 | 1.45e-03 | 1.36e-02 | 39 |
GO:200102025 | Thyroid | HT | regulation of response to DNA damage stimulus | 27/1272 | 219/18723 | 1.95e-03 | 1.73e-02 | 27 |
GO:190225328 | Thyroid | HT | regulation of intrinsic apoptotic signaling pathway by p53 class mediator | 7/1272 | 29/18723 | 2.73e-03 | 2.25e-02 | 7 |
GO:003304418 | Thyroid | HT | regulation of chromosome organization | 22/1272 | 187/18723 | 8.36e-03 | 4.79e-02 | 22 |
GO:0009896113 | Thyroid | PTC | positive regulation of catabolic process | 278/5968 | 492/18723 | 3.35e-30 | 2.64e-27 | 278 |
GO:0031331113 | Thyroid | PTC | positive regulation of cellular catabolic process | 249/5968 | 427/18723 | 5.28e-30 | 3.58e-27 | 249 |
GO:0042176113 | Thyroid | PTC | regulation of protein catabolic process | 231/5968 | 391/18723 | 4.76e-29 | 2.14e-26 | 231 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0516624 | Breast | IDC | Human T-cell leukemia virus 1 infection | 40/867 | 222/8465 | 2.52e-04 | 2.21e-03 | 1.66e-03 | 40 |
hsa0516634 | Breast | IDC | Human T-cell leukemia virus 1 infection | 40/867 | 222/8465 | 2.52e-04 | 2.21e-03 | 1.66e-03 | 40 |
hsa0516642 | Breast | DCIS | Human T-cell leukemia virus 1 infection | 41/846 | 222/8465 | 7.03e-05 | 6.88e-04 | 5.07e-04 | 41 |
hsa0516652 | Breast | DCIS | Human T-cell leukemia virus 1 infection | 41/846 | 222/8465 | 7.03e-05 | 6.88e-04 | 5.07e-04 | 41 |
hsa0516639 | Esophagus | HGIN | Human T-cell leukemia virus 1 infection | 51/1383 | 222/8465 | 5.84e-03 | 4.05e-02 | 3.22e-02 | 51 |
hsa041109 | Esophagus | HGIN | Cell cycle | 38/1383 | 157/8465 | 6.70e-03 | 4.37e-02 | 3.47e-02 | 38 |
hsa05166114 | Esophagus | HGIN | Human T-cell leukemia virus 1 infection | 51/1383 | 222/8465 | 5.84e-03 | 4.05e-02 | 3.22e-02 | 51 |
hsa0411016 | Esophagus | HGIN | Cell cycle | 38/1383 | 157/8465 | 6.70e-03 | 4.37e-02 | 3.47e-02 | 38 |
hsa0411023 | Esophagus | ESCC | Cell cycle | 126/4205 | 157/8465 | 1.34e-15 | 5.60e-14 | 2.87e-14 | 126 |
hsa05166211 | Esophagus | ESCC | Human T-cell leukemia virus 1 infection | 164/4205 | 222/8465 | 8.13e-14 | 2.09e-12 | 1.07e-12 | 164 |
hsa041146 | Esophagus | ESCC | Oocyte meiosis | 77/4205 | 131/8465 | 2.19e-02 | 4.80e-02 | 2.46e-02 | 77 |
hsa0411033 | Esophagus | ESCC | Cell cycle | 126/4205 | 157/8465 | 1.34e-15 | 5.60e-14 | 2.87e-14 | 126 |
hsa05166310 | Esophagus | ESCC | Human T-cell leukemia virus 1 infection | 164/4205 | 222/8465 | 8.13e-14 | 2.09e-12 | 1.07e-12 | 164 |
hsa0411411 | Esophagus | ESCC | Oocyte meiosis | 77/4205 | 131/8465 | 2.19e-02 | 4.80e-02 | 2.46e-02 | 77 |
hsa041102 | Liver | HCC | Cell cycle | 106/4020 | 157/8465 | 2.54e-07 | 3.04e-06 | 1.69e-06 | 106 |
hsa0516622 | Liver | HCC | Human T-cell leukemia virus 1 infection | 139/4020 | 222/8465 | 3.17e-06 | 2.79e-05 | 1.55e-05 | 139 |
hsa041103 | Liver | HCC | Cell cycle | 106/4020 | 157/8465 | 2.54e-07 | 3.04e-06 | 1.69e-06 | 106 |
hsa0516632 | Liver | HCC | Human T-cell leukemia virus 1 infection | 139/4020 | 222/8465 | 3.17e-06 | 2.79e-05 | 1.55e-05 | 139 |
hsa041108 | Oral cavity | OSCC | Cell cycle | 118/3704 | 157/8465 | 7.15e-16 | 2.66e-14 | 1.35e-14 | 118 |
hsa0516630 | Oral cavity | OSCC | Human T-cell leukemia virus 1 infection | 150/3704 | 222/8465 | 3.68e-13 | 7.26e-12 | 3.70e-12 | 150 |
Page: 1 2 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
PTTG1 | SNV | Missense_Mutation | c.385N>A | p.Asp129Asn | p.D129N | O95997 | protein_coding | deleterious(0.03) | benign(0.125) | TCGA-BH-A204-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
PTTG1 | SNV | Missense_Mutation | rs763093561 | c.351N>A | p.Phe117Leu | p.F117L | O95997 | protein_coding | tolerated(0.5) | benign(0.007) | TCGA-AA-A010-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Chemotherapy | folinic | CR |
PTTG1 | SNV | Missense_Mutation | novel | c.491C>A | p.Pro164His | p.P164H | O95997 | protein_coding | deleterious(0) | probably_damaging(0.992) | TCGA-A5-A1OF-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
PTTG1 | SNV | Missense_Mutation | novel | c.551N>A | p.Ser184Asn | p.S184N | O95997 | protein_coding | tolerated(0.31) | possibly_damaging(0.459) | TCGA-AX-A06F-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatin | SD |
PTTG1 | SNV | Missense_Mutation | c.329N>T | p.Ala110Val | p.A110V | O95997 | protein_coding | tolerated(0.2) | benign(0.171) | TCGA-AX-A1CE-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unspecific | Paclitaxel | SD | |
PTTG1 | SNV | Missense_Mutation | c.385N>A | p.Asp129Asn | p.D129N | O95997 | protein_coding | deleterious(0.03) | benign(0.125) | TCGA-B5-A11U-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD | |
PTTG1 | SNV | Missense_Mutation | novel | c.391C>T | p.Pro131Ser | p.P131S | O95997 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-B5-A3FA-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
PTTG1 | SNV | Missense_Mutation | novel | c.584N>T | p.Pro195Leu | p.P195L | O95997 | protein_coding | deleterious(0) | possibly_damaging(0.661) | TCGA-EO-A3KX-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
PTTG1 | SNV | Missense_Mutation | novel | c.583N>A | p.Pro195Thr | p.P195T | O95997 | protein_coding | deleterious(0) | possibly_damaging(0.661) | TCGA-DD-AAC9-01 | Liver | liver hepatocellular carcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
PTTG1 | SNV | Missense_Mutation | c.410C>G | p.Ala137Gly | p.A137G | O95997 | protein_coding | deleterious(0.02) | possibly_damaging(0.715) | TCGA-05-4427-01 | Lung | lung adenocarcinoma | Female | >=65 | I/II | Chemotherapy | cisplatin | CR |
Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |